Morgan Stanley’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q2 | – | Sell |
-3,919
| Closed | -$1K | – | 6866 |
|
|
2018
Q1 | $1K | Sell |
3,919
-78
| -2% | -$116 | ﹤0.01% | 6582 |
|
|
2017
Q4 | $7K | Sell |
3,997
-2,663
| -40% | -$4.58K | ﹤0.01% | 6295 |
|
|
2017
Q3 | $9K | Sell |
6,660
-4,174
| -39% | -$5.93K | ﹤0.01% | 6204 |
|
|
2017
Q2 | $17K | Sell |
10,834
-2,007
| -16% | -$4.5K | ﹤0.01% | 6127 |
|
|
2017
Q1 | $44K | Sell |
12,841
-5,016
| -28% | -$23.7K | ﹤0.01% | 5869 |
|
|
2016
Q4 | $92K | Buy |
17,857
+15,911
| +818% | +$275K | ﹤0.01% | 5599 |
|
|
2016
Q3 | $48K | Buy |
1,946
+726
| +60% | +$18.3K | ﹤0.01% | 5611 |
|
|
2016
Q2 | $30K | Buy |
1,220
+208
| +21% | +$5.88K | ﹤0.01% | 5710 |
|
|
2016
Q1 | $30K | Sell |
1,012
-123
| -11% | -$3.34K | ﹤0.01% | 5801 |
|
|
2015
Q4 | $43K | Sell |
1,135
-16,690
| -94% | -$737K | ﹤0.01% | 5775 |
|
|
2015
Q3 | $869K | Buy |
17,825
+17,250
| +3,000% | +$1.21M | ﹤0.01% | 4220 |
|
|
2015
Q2 | $40K | Sell |
575
-177
| -24% | -$8.19K | ﹤0.01% | 5936 |
|
|
2015
Q1 | $27K | Buy |
752
+747
| +14,940% | +$22.1K | ﹤0.01% | 5984 |
|
|
2014
Q4 | $0 | Hold |
5
| – | – | ﹤0.01% | 6760 |
|
|
2014
Q3 | $0 | Buy |
5
+1
| +25% | +$21 | ﹤0.01% | 6740 |
|
|
2014
Q2 | $0 | Hold |
4
| – | – | ﹤0.01% | 6671 |
|
|
2014
Q1 | $0 | Buy |
+4
| New | +$102 | ﹤0.01% | 6608 |
|
|
2013
Q3 | – | Sell |
-156
| Closed | -$5K | – | 5436 |
|
|
2013
Q2 | $5K | Buy |
+156
| New | +$5.82K | ﹤0.01% | 5313 |
|
Other funds holding ANTH
Morgan Stanley's ANTH Position: Q2 2018 in Review
Morgan Stanley sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q2 2018, closing a stake of 3,919 shares — an estimated $1K sold.
Morgan Stanley first reported a position in ANTH in Q2 2013 and held it in 18 quarters. The position peaked at $869K in Q3 2015. 5 funds tracked by Wall St. Rank hold ANTH as of Q2 2018.
- Morgan Stanley reported no remaining Anthera Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
- Morgan Stanley sold 3,919 Anthera Pharmaceuticals, Inc. shares in Q2 2018, an estimated $1K.
- Morgan Stanley first reported a position in Anthera Pharmaceuticals, Inc. in Q2 2013 and held it in 18 quarters.
- Morgan Stanley's Anthera Pharmaceuticals, Inc. position peaked at $869K in Q3 2015.
- 5 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q2 2018.
Based on Morgan Stanley's 13F filing for Q2 2018, filed 14 Aug 2018.